

# Heike Bunjes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6544655/publications.pdf>

Version: 2024-02-01

83  
papers

3,992  
citations

159358

30  
h-index

118652

62  
g-index

84  
all docs

84  
docs citations

84  
times ranked

4132  
citing authors

#	ARTICLE	IF	CITATIONS
1	Spatially and Temporally Controllable BMP-2 and TGF- $\beta$ 3 Double Release From Polycaprolactone Fiber Scaffolds via Chitosan-Based Polyelectrolyte Coatings. ACS Biomaterials Science and Engineering, 2024, 10, 89-98.	2.6	3
2	Tablet Disintegration and Dispersion under In Vivo-like Hydrodynamic Conditions. Pharmaceutics, 2022, 14, 208.	2.0	2
3	Horseshoe lamination mixer (HLM) sets new standards in the production of monodisperse lipid nanoparticles. Lab on A Chip, 2022, 22, 3025-3044.	3.1	6
4	Varying the sustained release of BMP-2 from chitosan nanogel-functionalized polycaprolactone fiber mats by different polycaprolactone surface modifications. Journal of Biomedical Materials Research - Part A, 2021, 109, 600-614.	2.1	13
5	Protective Filtration for Microfluidic Nanoparticle Precipitation for Pharmaceutical Applications. Chemical Engineering and Technology, 2021, 44, 457-464.	0.9	5
6	Transfer of Lipophilic Drugs from Nanoemulsions into Lipid-Containing Alginate Microspheres. Pharmaceutics, 2021, 13, 173.	2.0	3
7	An improved method for the simultaneous determination of water uptake and swelling of tablets. International Journal of Pharmaceutics, 2021, 595, 120229.	2.6	4
8	Formulation of Cannabidiol in Colloidal Lipid Carriers. Molecules, 2021, 26, 1469.	1.7	20
9	Drug localization and its effect on the physical stability of poloxamer 188-stabilized colloidal lipid emulsions. International Journal of Pharmaceutics, 2021, 599, 120394.	2.6	7
10	ELISA- and Activity Assay-Based Quantification of BMP-2 Released In Vitro Can Be Biased by Solubility in $\alpha$ -Physiological Buffers and an Interfering Effect of Chitosan. Pharmaceutics, 2021, 13, 582.	2.0	2
11	Continuous Production of Lipid Nanoparticles by Ultrasound-Assisted Microfluidic Antisolvent Precipitation. Chemical Engineering and Technology, 2021, 44, 1641-1650.	0.9	6
12	Transfer Investigations of Lipophilic Drugs from Lipid Nanoemulsions to Lipophilic Acceptors: Contributing Effects of Cholesteryl Esters and Albumin as Acceptor Structures. Pharmaceutics, 2021, 14, 865.	1.7	3
13	Influence of process and formulation parameters on the preparation of solid lipid nanoparticles by dual centrifugation. International Journal of Pharmaceutics: X, 2021, 3, 100085.	1.2	9
14	Goodbye fouling: a unique coaxial lamination mixer (CLM) enabled by two-photon polymerization for the stable production of monodisperse drug carrier nanoparticles. Lab on A Chip, 2021, 21, 2178-2193.	3.1	15
15	Premix Membrane Emulsification: Preparation and Stability of Medium-Chain Triglyceride Emulsions with Droplet Sizes below 100 nm. Molecules, 2021, 26, 6029.	1.7	4
16	Tablet formulation development focusing on the functional behaviour of water uptake and swelling. International Journal of Pharmaceutics: X, 2021, 3, 100103.	1.2	3
17	Orodispersible Films: A Delivery Platform for Solid Lipid Nanoparticles?. Pharmaceutics, 2021, 13, 2162.	2.0	13
18	Suitability of phosphatidylcholine-based formulations for liquid filling in hard capsules. European Journal of Pharmaceutical Sciences, 2020, 153, 105470.	1.9	3

#	ARTICLE	IF	CITATIONS
19	Bone Morphogenetic Protein 2 (BMP-2) Aggregates Can be Solubilized by Albumin—Investigation of BMP-2 Aggregation by Light Scattering and Electrophoresis. <i>Pharmaceutics</i> , 2020, 12, 1143.	2.0	21
20	Influence of drug loading on the physical stability of phospholipid-stabilised colloidal lipid emulsions. <i>International Journal of Pharmaceutics: X</i> , 2020, 2, 100060.	1.2	6
21	Antisolvent precipitation of lipid nanoparticles in microfluidic systems – A comparative study. <i>International Journal of Pharmaceutics</i> , 2020, 579, 119167.	2.6	24
22	Self-dispersing formulations for the delivery of poorly soluble drugs – Miscibility of phosphatidylcholines with oils and fats. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 151, 209-219.	2.0	4
23	Influence of Formulation Parameters on Redispersibility of Naproxen Nanoparticles from Granules Produced in a Fluidized Bed Process. <i>Pharmaceutics</i> , 2020, 12, 363.	2.0	16
24	Spray drying of API nanosuspensions: Importance of drying temperature, type and content of matrix former and particle size for successful formulation and process development. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 152, 63-71.	2.0	10
25	A Microfluidic Split-Flow Technology for Product Characterization in Continuous Low-Volume Nanoparticle Synthesis. <i>Micromachines</i> , 2019, 10, 179.	1.4	11
26	Stabilized Production of Lipid Nanoparticles of Tunable Size in Taylor Flow Glass Devices with High-Surface-Quality 3D Microchannels. <i>Micromachines</i> , 2019, 10, 220.	1.4	22
27	Influence of membrane material on the production of colloidal emulsions by premix membrane emulsification. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 126, 140-148.	2.0	22
28	Parameters influencing the course of passive drug loading into lipid nanoemulsions. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 126, 123-131.	2.0	14
29	Novel strategies for the formulation and processing of poorly water-soluble drugs. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 126, 40-56.	2.0	110
30	Carrier characteristics influence the kinetics of passive drug loading into lipid nanoemulsions. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 126, 132-139.	2.0	9
31	Heat Treatment of Poloxamer-Stabilized Triglyceride Nanodispersions: Effects and Underlying Mechanism. <i>Molecular Pharmaceutics</i> , 2018, 15, 3111-3120.	2.3	4
32	Drug release studies from lipid nanoparticles in physiological media by a new DSC method. <i>Journal of Controlled Release</i> , 2017, 256, 92-100.	4.8	15
33	Preparation of Nanoemulsions by Premix Membrane Emulsification: Which Parameters Have a Significant Influence on the Resulting Particle Size?. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2068-2076.	1.6	22
34	Evaluation of the drug loading capacity of different lipid nanoparticle dispersions by passive drug loading. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 117, 49-59.	2.0	33
35	Optically monitored segmented flow for controlled ultra-fast mixing and nanoparticle precipitation. <i>Microfluidics and Nanofluidics</i> , 2017, 21, 1.	1.0	24
36	Drug solubility in lipid nanocarriers: Influence of lipid matrix and available interfacial area. <i>International Journal of Pharmaceutics</i> , 2017, 529, 617-628.	2.6	23

#	ARTICLE	IF	CITATIONS
37	Control over Particle Size Distribution by Autoclaving Poloxamer-Stabilized Trimyrustin Nanodispersions. <i>Molecular Pharmaceutics</i> , 2016, 13, 3187-3195.	2.3	13
38	Preparation of lipid nanoemulsions by premix membrane emulsification with disposable materials. <i>International Journal of Pharmaceutics</i> , 2016, 511, 741-744.	2.6	14
39	Light and Electron Microscopy. <i>Advances in Delivery Science and Technology</i> , 2016, , 491-522.	0.4	2
40	Determining drug release rates of hydrophobic compounds from nanocarriers. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2016, 374, 20150128.	1.6	17
41	Alkynyl gold(I) phosphane complexes: Evaluation of structure-activity-relationships for the phosphane ligands, effects on key signaling proteins and preliminary in-vivo studies with a nanoformulated complex. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 140-148.	1.5	53
42	Instrumented small scale extruder to investigate the influence of process parameters during premix membrane emulsification. <i>Chemical Engineering Journal</i> , 2016, 284, 716-723.	6.6	21
43	Development of a new approach to investigating the drug transfer from colloidal carrier systems applying lipid nanosuspension-containing alginate microbeads as acceptor. <i>International Journal of Pharmaceutics</i> , 2015, 489, 203-209.	2.6	15
44	Stability of the Metastable $\beta$ -Polymorph in Solid Triglyceride Drug-Carrier Nanoparticles. <i>Langmuir</i> , 2015, 31, 6663-6674.	1.6	17
45	Challenges in Nanogrinding of Active Pharmaceutical Ingredients. <i>Chemical Engineering and Technology</i> , 2014, 37, 840-846.	0.9	36
46	Lipid nanoparticles: Drug localization is substance-specific and achievable load depends on the size and physical state of the particles. <i>Journal of Controlled Release</i> , 2014, 189, 54-64.	4.8	37
47	Evaluation of Shirasu Porous Glass (SPG) membrane emulsification for the preparation of colloidal lipid drug carrier dispersions. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 87, 178-186.	2.0	41
48	Incorporation of lipid nanoparticles into calcium alginate beads and characterization of the encapsulated particles by differential scanning calorimetry. <i>Food Hydrocolloids</i> , 2013, 30, 567-575.	5.6	34
49	Encapsulation of proteins in hydrogel carrier systems for controlled drug delivery: Influence of network structure and drug size on release rate. <i>Journal of Biotechnology</i> , 2013, 163, 243-249.	1.9	106
50	Mobility of Green Fluorescent Protein in Hydrogel-Based Drug-Delivery Systems Studied by Anisotropy and Fluorescence Recovery After Photobleaching. <i>Macromolecular Bioscience</i> , 2013, 13, 215-226.	2.1	11
51	Influence of membrane structure on the preparation of colloidal lipid dispersions by premix membrane emulsification. <i>International Journal of Pharmaceutics</i> , 2013, 446, 59-62.	2.6	10
52	Variations in polyethylene glycol brands and their influence on the preparation process of hydrogel microspheres. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 1215-1218.	2.0	3
53	Parenteral formulation of an antileishmanial drug candidate - Tackling poor solubility, chemical instability, and polymorphism. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 511-520.	2.0	19
54	PEGylation of supercooled smectic cholesteryl myristate nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 81, 409-417.	2.0	9

#	ARTICLE	IF	CITATIONS
55	Hydroxyethyl starch-based polymers for the controlled release of biomacromolecules from hydrogel microspheres. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 81, 573-581.	2.0	36
56	Chemical stability of phospholipid-stabilized supercooled smectic cholesteryl myristate nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 82, 262-271.	2.0	10
57	Preparation of Nanoemulsions and Solid Lipid Nanoparticles by Premix Membrane Emulsification. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 2479-2489.	1.6	50
58	Comparison of in vitro and in vivo protein release from hydrogel systems. <i>Journal of Controlled Release</i> , 2012, 162, 127-133.	4.8	23
59	The physical state of lipid nanoparticles influences their effect on in vitro cell viability. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 79, 150-161.	2.0	51
60	Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. <i>International Journal of Pharmaceutics</i> , 2011, 417, 120-137.	2.6	254
61	Comparison of different protein concentration techniques within preformulation development. <i>International Journal of Pharmaceutics</i> , 2011, 421, 120-129.	2.6	16
62	Structural properties of solid lipid based colloidal drug delivery systems. <i>Current Opinion in Colloid and Interface Science</i> , 2011, 16, 405-411.	3.4	86
63	Thermotropic liquid crystalline drugs. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 807-816.	1.2	43
64	Influence of stabilizer systems on the properties and phase behavior of supercooled smectic nanoparticles. <i>Journal of Colloid and Interface Science</i> , 2010, 350, 229-239.	5.0	16
65	Flow Cytometry as a New Approach To Investigate Drug Transfer between Lipid Particles. <i>Molecular Pharmaceutics</i> , 2010, 7, 350-363.	2.3	63
66	Relevant shaking stress conditions for antibody preformulation development. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010, 74, 139-147.	2.0	47
67	Lipid nanoparticles for the delivery of poorly water-soluble drugs. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 1637-1645.	1.2	190
68	Supercooled smectic nanoparticles: Influence of the matrix composition and in vitro cytotoxicity. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 38, 238-248.	1.9	11
69	Poly(vinyl alcohol) as Emulsifier Stabilizes Solid Triglyceride Drug Carrier Nanoparticles in the $\beta'$ -Modification. <i>Molecular Pharmaceutics</i> , 2009, 6, 105-120.	2.3	70
70	Visualizing the Structure of Triglyceride Nanoparticles in Different Crystal Modifications. <i>Langmuir</i> , 2007, 23, 4005-4011.	1.6	169
71	Drug Release from Differently Structured Monoolein/Poloxamer Nanodispersions Studied with Differential Pulse Polarography and Ultrafiltration at Low Pressure. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 1564-1575.	1.6	41
72	Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 379-402.	6.6	266

#	ARTICLE	IF	CITATIONS
73	Transformation of vesicular into cubic nanoparticles by autoclaving of aqueous monoolein/poloxamer dispersions. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 27, 44-53.	1.9	60
74	Saturated phospholipids promote crystallization but slow down polymorphic transitions in triglyceride nanoparticles. <i>Journal of Controlled Release</i> , 2005, 107, 229-243.	4.8	122
75	Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. <i>Journal of Controlled Release</i> , 2004, 95, 217-227.	4.8	390
76	Characterization of Solid Lipid Nano-and Microparticles. , 2004, , 41-66.		3
77	Influence of emulsifiers on the crystallization of solid lipid nanoparticles. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1509-1520.	1.6	163
78	Effects of surfactants on the crystallization and polymorphism of lipid nanoparticles. , 2002, , 7-10.		25
79	Incorporation of the model drug ubidecarenone into solid lipid nanoparticles. <i>Pharmaceutical Research</i> , 2001, 18, 287-293.	1.7	85
80	Effect of Particle Size on Colloidal Solid Triglycerides. <i>Langmuir</i> , 2000, 16, 5234-5241.	1.6	156
81	Observation of Size-Dependent Melting in Lipid Nanoparticles. <i>Journal of Physical Chemistry B</i> , 1999, 103, 10373-10377.	1.2	67
82	Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. <i>International Journal of Pharmaceutics</i> , 1996, 129, 159-173.	2.6	371
83	Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix?. <i>International Journal of Pharmaceutics</i> , 1995, 115, 129-131.	2.6	133